2022-06-23 17:26:41,292 (('a23295227.s4', 'Now, inhibition studies showed that fidarestat was indeed 1300-fold more selective for AR as compared to AKR1B10, while the change of Val to Leu (found in AR) caused a 20-fold decrease in the IC50 value with fidarestat. '), ('T20', 132, 135, 'Val', 'CHEMICAL'))
2022-06-23 17:26:41,292 (('a23295227.s4', 'Now, inhibition studies showed that fidarestat was indeed 1300-fold more selective for AR as compared to AKR1B10, while the change of Val to Leu (found in AR) caused a 20-fold decrease in the IC50 value with fidarestat. '), ('T21', 139, 142, 'Leu', 'CHEMICAL'))
2022-06-23 17:26:41,306 (('a23256725.s4', 'Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (GnRH) antagonist abolishes this effect. '), ('T2', 138, 169, 'gonadotrophin releasing hormone', 'CHEMICAL'))
2022-06-23 17:26:41,306 (('a23256725.s4', 'Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (GnRH) antagonist abolishes this effect. '), ('T3', 171, 175, 'GnRH', 'CHEMICAL'))
2022-06-23 17:26:41,314 (('a15740719.s0', 'Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.'), ('T35', 129, 137, 'oxytocin', 'CHEMICAL'))
2022-06-23 17:26:41,314 (('a15740719.s1', 'We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin. '), ('T20', 224, 232, 'oxytocin', 'CHEMICAL'))
2022-06-23 17:26:41,325 (('a1472079.s2', 'In contrast, in native rat liver microsomes, glucuronidation of 4-OHCIPC was increased by cadmium through activation of microsomal 4-OHCIPC glucuronosyl transferase. '), ('T42', 140, 164, 'glucuronosyl transferase', 'GENE-N'))
2022-06-23 17:26:41,351 (('a16982784.s1', 'Among the TEM-type extended-spectrum beta-lactamases (ESBLs), an amino acid change at Ambler position 104 (Glu to Lys) results in increased resistance to ceftazidime and cefotaxime when found with other substitutions (e.g., Gly238Ser and Arg164Ser). '), ('T1', 108, 111, 'Glu', 'CHEMICAL'))
2022-06-23 17:26:41,351 (('a16982784.s1', 'Among the TEM-type extended-spectrum beta-lactamases (ESBLs), an amino acid change at Ambler position 104 (Glu to Lys) results in increased resistance to ceftazidime and cefotaxime when found with other substitutions (e.g., Gly238Ser and Arg164Ser). '), ('T3', 115, 118, 'Lys', 'CHEMICAL'))
2022-06-23 17:26:41,374 (('a23202585.s2', 'Prominent mechanistic models imply cooperation of the ISWI ATPase domain with a C-terminal DNA-binding function residing in the HAND-SANT-SLIDE (HSS) domain. '), ('T1', 80, 81, 'C', 'CHEMICAL'))
2022-06-23 17:26:41,393 (('a8469910.s0', 'Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated prolactin production without modifying the production of inositolphosphates in GH4C1 pituitary cells.'), ('T17', 75, 78, 'TRH', 'CHEMICAL'))
2022-06-23 17:26:41,393 (('a8469910.s0', 'Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated prolactin production without modifying the production of inositolphosphates in GH4C1 pituitary cells.'), ('T16', 61, 73, 'thyroliberin', 'CHEMICAL'))
2022-06-23 17:26:41,393 (('a8469910.s2', 'We report that the phospholipase A2 and diacylglycerol lipase inhibitor quinacrine (1-10 mumol l-1) inhibited the thyroliberin stimulated prolactin (rPRL) production in a dose-dependent way in a rat pituitary tumour cell line (GH4Cl cells). '), ('T3', 114, 126, 'thyroliberin', 'CHEMICAL'))
2022-06-23 17:26:41,393 (('a8469910.s3', 'The lipoxygenase inhibitor nafazatrom (5-50 mumol-1) also dose-dependently inhibited the thyroliberin stimulated rPRL production, while the cyclo-oxygenase inhibitor indomethacin had no such effect on rPRL production. '), ('T5', 88, 100, 'thyroliberin', 'CHEMICAL'))
2022-06-23 17:26:41,414 (('a11980628.s0', 'SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.'), ('T36', 17, 29, 'somatostatin', 'CHEMICAL'))
2022-06-23 17:26:41,414 (('a11980628.s1', 'OBJECTIVE: The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF) analog with a more universal binding profile similar to that of natural somatostatin, resulting in improved pharmacological properties and hence new therapeutic uses. '), ('T12', 205, 217, 'somatostatin', 'CHEMICAL'))
2022-06-23 17:26:41,419 (('a16370964.s6', 'Dual-mechanism antidepressants (e.g., duloxetine and venlafaxine) do not appear to disrupt glucose homeostatic dynamics, whereas nonselective hydrazine monoamine oxidase inhibitors (e.g., phenelzine) are associated with hypoglycaemia and an increased glucose disposal rate. '), ('T15', 148, 165, 'monoamine oxidase', 'GENE-N'))
2022-06-23 17:26:41,438 (('a23435367.s1', 'Ferredoxin 1 (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues. '), ('T1', 119, 126, 'steroid', 'CHEMICAL'))
2022-06-23 17:26:41,444 (('a23522564.s2', 'The gp41 subunit contains several functional domains: the N-terminal heptad repeat (NHR) domains fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate. '), ('T1', 58, 59, 'N', 'CHEMICAL'))
2022-06-23 17:26:41,451 (('a17553661.s5', 'HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-4-HNE catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells. '), ('T27', 103, 108, '4-HNE', 'CHEMICAL'))
2022-06-23 17:26:41,463 (('a23473037.s5', 'Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a leucine-to-proline mutation at residue 107. '), ('T2', 120, 127, 'proline', 'CHEMICAL'))
2022-06-23 17:26:41,463 (('a23473037.s5', 'Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a leucine-to-proline mutation at residue 107. '), ('T1', 109, 116, 'leucine', 'CHEMICAL'))
2022-06-23 17:26:41,477 (('a23142425.s9', 'Subjects carrying the UGT2B7 268 His/Tyr or Tyr/Tyr genotype had significantly lower total NNAL than those carrying His/His genotype. '), ('T4', 30, 33, 'Tyr', 'CHEMICAL'))
2022-06-23 17:26:41,477 (('a23142425.s9', 'Subjects carrying the UGT2B7 268 His/Tyr or Tyr/Tyr genotype had significantly lower total NNAL than those carrying His/His genotype. '), ('T3', 26, 29, 'His', 'CHEMICAL'))
2022-06-23 17:26:41,478 (('a10381508.s1', 'Factor IXR94S is a naturally occurring hemophilia B defect, which results from an Arg 94 to Ser mutation in the second epidermal growth factor (EGF)-like module of factor IX. '), ('T11', 93, 96, 'Ser', 'CHEMICAL'))
2022-06-23 17:26:41,478 (('a10381508.s1', 'Factor IXR94S is a naturally occurring hemophilia B defect, which results from an Arg 94 to Ser mutation in the second epidermal growth factor (EGF)-like module of factor IX. '), ('T10', 83, 86, 'Arg', 'CHEMICAL'))
2022-06-23 17:26:41,478 (('a10381508.s2', 'Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX. '), ('T32', 21, 25, 'R94S', 'GENE-N'))
2022-06-23 17:26:41,496 (('a23249624.s2', 'Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma. '), ('T9', 149, 162, 'glutamic acid', 'CHEMICAL'))
2022-06-23 17:26:41,496 (('a23249624.s2', 'Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma. '), ('T8', 135, 141, 'valine', 'CHEMICAL'))
2022-06-23 17:26:41,497 (('a9760035.s3', 'Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as oxytocin. '), ('T28', 160, 168, 'oxytocin', 'CHEMICAL'))
2022-06-23 17:26:41,497 (('a9627096.s5', 'Furthermore, despite of their affinities for NT2 receptor, the Ca2+ responses to potent NT1 agonists, neurotensin or JMV449 ([Lys8-(CH2NH)-Lys9]Pro-Tyr-Ile-Leu, a peptidase resistant analogue of neurotensin) were much smaller than that observed with SR48692. '), ('T10', 99, 110, 'neurotensin', 'CHEMICAL'))
2022-06-23 17:26:41,532 (('a17202804.s0', 'Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.'), ('T25', 1, 31, 'Gonadotropin-releasing hormone', 'CHEMICAL'))
2022-06-23 17:26:41,546 (('a22935616.s4', 'While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/Ser473. '), ('T4', 128, 131, 'Ser', 'CHEMICAL'))
2022-06-23 17:26:41,546 (('a22935616.s4', 'While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/Ser473. '), ('T3', 121, 124, 'Ser', 'CHEMICAL'))
2022-06-23 17:26:41,563 (('a23548896.s0', 'Identification of a new interaction mode between the Src homology 2 (SH2) domain of C-terminal Src kinase (Csk) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG).'), ('T6', 85, 86, 'C', 'CHEMICAL'))
2022-06-23 17:26:41,563 (('a23548896.s4', 'Here we report the solution structure of the SH2 domain of C-terminal Src kinase (Csk) in complex with a longer phosphopeptide from Csk-binding protein (Cbp). '), ('T3', 57, 58, 'C', 'CHEMICAL'))
2022-06-23 17:26:41,585 (('a22370636.s4', 'Whole-exome analysis of the Pik3ca(H1047R)-driven mammary tumors identified multiple mutations, including Trp53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors. '), ('T2', 104, 107, 'Trp', 'CHEMICAL'))
2022-06-23 17:45:03,342 ('No tokens found:', ([132, 135], 'Val', 'CHEBI:30015'), 'Now, inhibition studies showed t fidarestat at was indeed 1300-fold more selective  AR AR as compared AKR1B10 10, while the change Val_to_Leu eu (found AR AR) caused a 20-fold decrease in the IC50 value w fidarestat at. ', 'Now|,|inhibition|studies|showed|t|fidarestat|at|was|indeed|1300-fold|more|selective| |AR|AR|as|compared|AKR1B10|10|,|while|the|change|Val_to_Leu|eu|(|found|AR|AR|)|caused|a|20-fold|decrease|in|the|IC50|value|w|fidarestat|at|.')
2022-06-23 17:45:03,343 ('No tokens found:', ([139, 142], 'Leu', 'CHEBI:30006'), 'Now, inhibition studies showed t fidarestat at was indeed 1300-fold more selective  AR AR as compared AKR1B10 10, while the change Val_to_Leu eu (found AR AR) caused a 20-fold decrease in the IC50 value w fidarestat at. ', 'Now|,|inhibition|studies|showed|t|fidarestat|at|was|indeed|1300-fold|more|selective| |AR|AR|as|compared|AKR1B10|10|,|while|the|change|Val_to_Leu|eu|(|found|AR|AR|)|caused|a|20-fold|decrease|in|the|IC50|value|w|fidarestat|at|.')
2022-06-23 17:47:19,306 ('Head token conflict:', 'a23256725.s4.uT2', ([138, 169], 'gonadotrophin releasing hormone', 'GO:0097210'))
2022-06-23 17:47:19,308 ('Head token conflict:', 'a23256725.s4.uT3', ([171, 175], 'GnRH', 'GO_0000003'))
2022-06-23 17:48:33,921 ('Head token conflict:', 'a15740719.s0.uT35', ([129, 137], 'oxytocin', 'GO:0004784'))
2022-06-23 17:48:33,969 ('Head token conflict:', 'a15740719.s1.uT20', ([224, 232], 'oxytocin', 'GO:0004784'))
2022-06-23 17:50:12,945 ('No tokens found:', ([131, 152], '4-OHCIPC glucuronosyl', 'CHEBI:24303'), 'In contrast, in native rat liver microsomes, glucuronidation o 4-OHCIPC  was increased b cadmium  through activation of microsoma 4-OHCIPC_glucuronosyl_transferase . ', 'In|contrast|,|in|native|rat|liver|microsomes|,|glucuronidation|o|4-OHCIPC| |was|increased|b|cadmium| |through|activation|of|microsoma|4-OHCIPC_glucuronosyl_transferase|.')
2022-06-23 17:50:12,946 ('No tokens found:', ([140, 164], 'glucuronosyl transferase', 'GO:0015779'), 'In contrast, in native rat liver microsomes, glucuronidation o 4-OHCIPC  was increased b cadmium  through activation of microsoma 4-OHCIPC_glucuronosyl_transferase . ', 'In|contrast|,|in|native|rat|liver|microsomes|,|glucuronidation|o|4-OHCIPC| |was|increased|b|cadmium| |through|activation|of|microsoma|4-OHCIPC_glucuronosyl_transferase|.')
2022-06-23 17:54:14,149 ('No tokens found:', ([108, 111], 'Glu', 'CHEBI:29972'), 'Among the TEM-type_extended-spectrum_beta-lactamases  ESBLs , an amino_acid change at Ambler position 104  Glu_to_Lys  results in increased resistance to ceftazidime and cefotaxime when found with other substitutions (e.g., Gly238Ser and Arg164Ser . ', 'Among|the|TEM|-|type_extended|-|spectrum_beta|-|lactamases| |ESBLs|,|an|amino_acid|change|at|Ambler|position|104| |Glu_to_Lys| |results|in|increased|resistance|to|ceftazidime|and|cefotaxime|when|found|with|other|substitutions|(|e.g.|,|Gly238Ser|and|Arg164Ser|.')
2022-06-23 17:54:14,150 ('No tokens found:', ([115, 118], 'Lys', 'CHEBI:18019'), 'Among the TEM-type_extended-spectrum_beta-lactamases  ESBLs , an amino_acid change at Ambler position 104  Glu_to_Lys  results in increased resistance to ceftazidime and cefotaxime when found with other substitutions (e.g., Gly238Ser and Arg164Ser . ', 'Among|the|TEM|-|type_extended|-|spectrum_beta|-|lactamases| |ESBLs|,|an|amino_acid|change|at|Ambler|position|104| |Glu_to_Lys| |results|in|increased|resistance|to|ceftazidime|and|cefotaxime|when|found|with|other|substitutions|(|e.g.|,|Gly238Ser|and|Arg164Ser|.')
2022-06-23 17:55:10,983 ('Head token conflict:', 'a23393127.s0.uT14', ([1, 5], 'GnRH', 'GO_0000003'))
2022-06-23 18:00:07,098 ('Head token conflict:', 'a8469910.s0.uT16', ([61, 73], 'thyroliberin', 'GO_0016239'))
2022-06-23 18:00:07,099 ('Head token conflict:', 'a8469910.s0.uT17', ([75, 78], 'TRH', 'GO_0001692'))
2022-06-23 18:00:07,197 ('Head token conflict:', 'a8469910.s2.uT3', ([114, 126], 'thyroliberin', 'GO_0016239'))
2022-06-23 18:00:07,242 ('Head token conflict:', 'a8469910.s3.uT5', ([88, 100], 'thyroliberin', 'GO_0016239'))
2022-06-23 18:00:25,375 ('Head token conflict:', 'a23211523.s0.uT10', ([21, 25], 'GnRH', 'GO_0000003'))
2022-06-23 18:03:05,171 ('Head token conflict:', 'a11980628.s0.uT36', ([17, 29], 'somatostatin', 'GO:0070253'))
2022-06-23 18:03:05,222 ('Head token conflict:', 'a11980628.s1.uT12', ([205, 217], 'somatostatin', 'GO:0070253'))
2022-06-23 18:03:43,245 ('No tokens found:', ([138, 157], 'hydrazine monoamine', 'CHEBI:144988'), 'Dual-mechanism antidepressants ( duloxetine tin venlafaxine xine) do not appear to di glucose cose homeostatic dynamics, whereas nonsele hydrazine_monoamine_oxidase dase inhibitors ( phenelzine zine) are associated with hypoglycaemia and an incr glucose cose disposal rate. ', 'Dual|-|mechanism|antidepressants|(|duloxetine|tin|venlafaxine|xine|)|do|not|appear|to|di|glucose|cose|homeostatic|dynamics|,|whereas|nonsele|hydrazine_monoamine_oxidase|dase|inhibitors|(|phenelzine|zine|)|are|associated|with|hypoglycaemia|and|an|incr|glucose|cose|disposal|rate|.')
2022-06-23 18:03:43,246 ('No tokens found:', ([148, 165], 'monoamine oxidase', 'GO:0004503'), 'Dual-mechanism antidepressants ( duloxetine tin venlafaxine xine) do not appear to di glucose cose homeostatic dynamics, whereas nonsele hydrazine_monoamine_oxidase dase inhibitors ( phenelzine zine) are associated with hypoglycaemia and an incr glucose cose disposal rate. ', 'Dual|-|mechanism|antidepressants|(|duloxetine|tin|venlafaxine|xine|)|do|not|appear|to|di|glucose|cose|homeostatic|dynamics|,|whereas|nonsele|hydrazine_monoamine_oxidase|dase|inhibitors|(|phenelzine|zine|)|are|associated|with|hypoglycaemia|and|an|incr|glucose|cose|disposal|rate|.')
2022-06-23 18:06:28,938 ('No tokens found:', ([119, 126], 'steroid', 'CHEBI:35341'), 'Ferredoxin_1  FDX1  adrenodoxin  is an iron sulfur protein that is involved in various metabolic processes, including steroid_hormone synthesis in mammalian tissues. ', 'Ferredoxin_1| |FDX1| |adrenodoxin| |is|an|iron|sulfur|protein|that|is|involved|in|various|metabolic|processes|,|including|steroid_hormone|synthesis|in|mammalian|tissues|.')
2022-06-23 18:08:21,887 ('No tokens found:', ([99, 104], 'GST-4', 'GO_0006487'), 'HepG2 cells transfected wit hGSTA4 TA4 vector construct exhibited high steady-s hGSTA4 TA4 mRNA,  GST-4-HNE HNE catalytic activities, but lower b glutathione  GSH GSH) concentrations relative to insert-free vector (control) cells. ', 'HepG2|cells|transfected|wit|hGSTA4|TA4|vector|construct|exhibited|high|steady|-|s|hGSTA4|TA4|mRNA|,| |GST-4-HNE|HNE|catalytic|activities|,|but|lower|b|glutathione| |GSH|GSH|)|concentrations|relative|to|insert|-|free|vector|(|control|)|cells|.')
2022-06-23 18:08:21,888 ('No tokens found:', ([103, 108], '4-HNE', 'CHEBI:32585'), 'HepG2 cells transfected wit hGSTA4 TA4 vector construct exhibited high steady-s hGSTA4 TA4 mRNA,  GST-4-HNE HNE catalytic activities, but lower b glutathione  GSH GSH) concentrations relative to insert-free vector (control) cells. ', 'HepG2|cells|transfected|wit|hGSTA4|TA4|vector|construct|exhibited|high|steady|-|s|hGSTA4|TA4|mRNA|,| |GST-4-HNE|HNE|catalytic|activities|,|but|lower|b|glutathione| |GSH|GSH|)|concentrations|relative|to|insert|-|free|vector|(|control|)|cells|.')
2022-06-23 18:10:08,957 ('Head token conflict:', 'a23473037.s5.uT1', ([109, 151], 'leucine-to-proline mutation at residue 107', 'GO:0070973'))
2022-06-23 18:10:08,959 ('No tokens found:', ([120, 127], 'proline', 'CHEBI:26271'), 'Direct and exome sequencing identified the presence of a T-to-C exchange in exon  SIRT1 RT1, corresponding  leucine-to-proline_mutation_at_residue_107 107. ', 'Direct|and|exome|sequencing|identified|the|presence|of|a|T|-|to|-|C|exchange|in|exon| |SIRT1|RT1|,|corresponding| |leucine|-|to|-|proline_mutation_at_residue_107|107|.')
2022-06-23 18:12:13,786 ('No tokens found:', ([26, 29], 'His', 'CHEBI:29979'), 'Subjects carr UGT2B7 268_His/Tyr Hi Tyr Tyr Tyr Tyr genotype had significantly low NNAL al NNAL than those  His His His His genotype. ', 'Subjects|carr|UGT2B7|268_His|/|Tyr|Hi|Tyr|Tyr|Tyr|Tyr|genotype|had|significantly|low|NNAL|al|NNAL|than|those| |His|His|His|His|genotype|.')
2022-06-23 18:12:20,142 ('No tokens found:', ([83, 86], 'Arg', 'CHEBI:29952'), 'Factor_IX 94S is a naturally occurring hemophilia B defect, which results from an Arg_94_to_Ser mutation in the second epidermal_growth_factor_(EGF)-like_module of factor_IX  ', 'Factor_IX|94S|is|a|naturally|occurring|hemophilia|B|defect|,|which|results|from|an|Arg_94_to_Ser|mutation|in|the|second|epidermal_growth_factor_(EGF)-like_module|of|factor_IX| ')
2022-06-23 18:12:20,143 ('No tokens found:', ([93, 96], 'Ser', 'CHEBI:29999'), 'Factor_IX 94S is a naturally occurring hemophilia B defect, which results from an Arg_94_to_Ser mutation in the second epidermal_growth_factor_(EGF)-like_module of factor_IX  ', 'Factor_IX|94S|is|a|naturally|occurring|hemophilia|B|defect|,|which|results|from|an|Arg_94_to_Ser|mutation|in|the|second|epidermal_growth_factor_(EGF)-like_module|of|factor_IX| ')
2022-06-23 18:12:20,195 ('No tokens found:', ([12, 21], 'factor IX', 'GO_0006355'), 'Recombinan factor_IXR94S  was activated b factor_XIa calcium  with an approximately 50-fold reduced rate and b factor_VIIa tissue_factor  phospholipi calcium  with an approximately 20-fold reduced rate compared with wild-typ factor_IX . ', 'Recombinan|factor_IXR94S| |was|activated|b|factor_XIa|calcium| |with|an|approximately|50-fold|reduced|rate|and|b|factor_VIIa|tissue_factor| |phospholipi|calcium| |with|an|approximately|20-fold|reduced|rate|compared|with|wild|-|typ|factor_IX|.')
2022-06-23 18:12:20,197 ('No tokens found:', ([21, 25], 'R94S', 'GO_0007186'), 'Recombinan factor_IXR94S  was activated b factor_XIa calcium  with an approximately 50-fold reduced rate and b factor_VIIa tissue_factor  phospholipi calcium  with an approximately 20-fold reduced rate compared with wild-typ factor_IX . ', 'Recombinan|factor_IXR94S| |was|activated|b|factor_XIa|calcium| |with|an|approximately|50-fold|reduced|rate|and|b|factor_VIIa|tissue_factor| |phospholipi|calcium| |with|an|approximately|20-fold|reduced|rate|compared|with|wild|-|typ|factor_IX|.')
2022-06-23 18:13:37,842 ('No tokens found:', ([261, 295], 'serine hydroxymethyl-transferase 1', 'GO:0047152'), 'METHODS, In 304 Caucasian American NTD families with myelomeningocele or anencephaly, we examined 28 polymorphisms in 11 gen folate_receptor_1  folate_receptor_2  solute_carrier_family_19_member_1  transcobalamin_II  methylenetetrahydrofolate_dehydrogenase_1  serine_hydroxymethyl-transferase_1,_5,10-methylenetetrahydrofolate te reducta MTHFR F 5-methyltetrahydrofolate-homo-cysteine_methyltransferase  5-methyltetrahydrofolate-homocysteine_methyltransferase_reductase  betaine-homocysteine_methyltransferase  BHMT MT),  cystathionine-beta-synthase se. ', 'METHODS|,|In|304|Caucasian|American|NTD|families|with|myelomeningocele|or|anencephaly|,|we|examined|28|polymorphisms|in|11|gen|folate_receptor_1| |folate_receptor_2| |solute_carrier_family_19_member_1| |transcobalamin_II| |methylenetetrahydrofolate_dehydrogenase_1| |serine_hydroxymethyl|-|transferase_1,_5,10-methylenetetrahydrofolate|te|reducta|MTHFR|F|5-methyltetrahydrofolate|-|homo|-|cysteine_methyltransferase| |5-methyltetrahydrofolate|-|homocysteine_methyltransferase_reductase| |betaine|-|homocysteine_methyltransferase| |BHMT|MT|)|,| |cystathionine|-|beta|-|synthase|se|.')
2022-06-23 18:13:37,843 ('No tokens found:', ([294, 327], '1, 5,10-methylenetetrahydrofolate', 'CHEBI:12071'), 'METHODS, In 304 Caucasian American NTD families with myelomeningocele or anencephaly, we examined 28 polymorphisms in 11 gen folate_receptor_1  folate_receptor_2  solute_carrier_family_19_member_1  transcobalamin_II  methylenetetrahydrofolate_dehydrogenase_1  serine_hydroxymethyl-transferase_1,_5,10-methylenetetrahydrofolate te reducta MTHFR F 5-methyltetrahydrofolate-homo-cysteine_methyltransferase  5-methyltetrahydrofolate-homocysteine_methyltransferase_reductase  betaine-homocysteine_methyltransferase  BHMT MT),  cystathionine-beta-synthase se. ', 'METHODS|,|In|304|Caucasian|American|NTD|families|with|myelomeningocele|or|anencephaly|,|we|examined|28|polymorphisms|in|11|gen|folate_receptor_1| |folate_receptor_2| |solute_carrier_family_19_member_1| |transcobalamin_II| |methylenetetrahydrofolate_dehydrogenase_1| |serine_hydroxymethyl|-|transferase_1,_5,10-methylenetetrahydrofolate|te|reducta|MTHFR|F|5-methyltetrahydrofolate|-|homo|-|cysteine_methyltransferase| |5-methyltetrahydrofolate|-|homocysteine_methyltransferase_reductase| |betaine|-|homocysteine_methyltransferase| |BHMT|MT|)|,| |cystathionine|-|beta|-|synthase|se|.')
2022-06-23 18:14:43,175 ('No tokens found:', ([135, 141], 'valine', 'CHEBI:27266'), 'Dabrafenib is  BRAF  (gene encodin serine/threonine-protein_kinase_B-Raf ) inhibitor that has been developed to selectively target th valine_600_to_glutamic_acid  substitution BRAF V600E )), which is commonly found in metastatic melanoma. ', 'Dabrafenib|is| |BRAF| |(|gene|encodin|serine|/|threonine|-|protein_kinase_B|-|Raf|)|inhibitor|that|has|been|developed|to|selectively|target|th|valine_600_to_glutamic_acid| |substitution|BRAF|V600E|)|)|,|which|is|commonly|found|in|metastatic|melanoma|.')
2022-06-23 18:14:43,177 ('No tokens found:', ([149, 162], 'glutamic acid', 'CHEBI:18237'), 'Dabrafenib is  BRAF  (gene encodin serine/threonine-protein_kinase_B-Raf ) inhibitor that has been developed to selectively target th valine_600_to_glutamic_acid  substitution BRAF V600E )), which is commonly found in metastatic melanoma. ', 'Dabrafenib|is| |BRAF| |(|gene|encodin|serine|/|threonine|-|protein_kinase_B|-|Raf|)|inhibitor|that|has|been|developed|to|selectively|target|th|valine_600_to_glutamic_acid| |substitution|BRAF|V600E|)|)|,|which|is|commonly|found|in|metastatic|melanoma|.')
2022-06-23 18:14:49,961 ('Head token conflict:', 'a9760035.s3.uT28', ([160, 168], 'oxytocin', 'GO:0004784'))
2022-06-23 18:14:52,277 ('Head token conflict:', 'a9627096.s5.uT10', ([99, 110], 'neurotensin', 'GO_0045745'))
2022-06-23 18:19:45,030 ('Head token conflict:', 'a17202804.s0.uT25', ([1, 31], 'Gonadotropin-releasing hormone', 'GO:0097210'))
2022-06-23 18:21:50,797 ('No tokens found:', ([121, 124], 'Ser', 'CHEBI:29999'), 'While DNA damage does not affect phosphorylation at  PDK-1 -1 s Thr350/Thr308 08 AKT-1 -1, it increased phosphorylation Ser517/Ser473 73. ', 'While|DNA|damage|does|not|affect|phosphorylation|at| |PDK-1|-1|s|Thr350/Thr308|08|AKT-1|-1|,|it|increased|phosphorylation|Ser517/Ser473|73|.')
2022-06-23 18:21:50,798 ('No tokens found:', ([128, 131], 'Ser', 'CHEBI:29999'), 'While DNA damage does not affect phosphorylation at  PDK-1 -1 s Thr350/Thr308 08 AKT-1 -1, it increased phosphorylation Ser517/Ser473 73. ', 'While|DNA|damage|does|not|affect|phosphorylation|at| |PDK-1|-1|s|Thr350/Thr308|08|AKT-1|-1|,|it|increased|phosphorylation|Ser517/Ser473|73|.')
2022-06-23 18:27:38,087 ('No tokens found:', ([104, 107], 'Trp', 'CHEBI:29954'), 'Whole-exome analysis of  Pik3ca H1047R 7R)-driven mammary tumors identified multiple mutations, includ Trp53 53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors. ', 'Whole|-|exome|analysis|of| |Pik3ca|H1047R|7R)-driven|mammary|tumors|identified|multiple|mutations|,|includ|Trp53|53|mutations|that|appeared|spontaneously|during|the|development|of|adenocarinoma|and|spindle|cell|tumors|.')
